Advertisement
UK markets close in 1 hour 50 minutes
  • FTSE 100

    8,149.42
    +2.56 (+0.03%)
     
  • FTSE 250

    20,168.28
    +47.92 (+0.24%)
     
  • AIM

    776.56
    +0.52 (+0.07%)
     
  • GBP/EUR

    1.1819
    -0.0026 (-0.22%)
     
  • GBP/USD

    1.2669
    -0.0017 (-0.14%)
     
  • Bitcoin GBP

    51,560.09
    -944.19 (-1.80%)
     
  • CMC Crypto 200

    1,369.35
    -18.81 (-1.35%)
     
  • S&P 500

    5,425.28
    -6.32 (-0.12%)
     
  • DOW

    38,441.27
    -147.89 (-0.38%)
     
  • CRUDE OIL

    79.01
    +0.56 (+0.71%)
     
  • GOLD FUTURES

    2,337.80
    -11.30 (-0.48%)
     
  • NIKKEI 225

    38,102.44
    -712.12 (-1.83%)
     
  • HANG SENG

    17,936.12
    -5.66 (-0.03%)
     
  • DAX

    18,060.69
    +58.67 (+0.33%)
     
  • CAC 40

    7,551.84
    +48.57 (+0.65%)
     

Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

HERCULES, Calif., May 23, 2024--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 10:30 AM Eastern Time (7:30 AM Pacific Time).

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523594442/en/

Contacts

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com